Ascentage Pharma Group (AAPG)

Executive Summary

Ascentage Pharma Group is a clinical-stage biotechnology company headquartered in Suzhou, China, focused on developing novel therapies for cancer, chronic hepatitis B, and age-related diseases. The company's drug discovery is centered on modulating apoptosis and autophagy pathways, with key programs targeting IAP, MDM2-p53, and Bcl-2/Bcl-xL proteins. Its leading asset, olverembatinib (HQP1351), is a BCR-ABL inhibitor for chronic myeloid leukemia (CML) that has shown promising efficacy in heavily pretreated patients, and is under regulatory review in China. Additionally, lisaftoclax (APG-2575), a Bcl-2 inhibitor, is being evaluated in several hematologic malignancies. Ascentage also has a preclinical pipeline for chronic hepatitis B, aiming for functional cure. The company is publicly traded on the Hong Kong Stock Exchange (ticker: AAPG).

Upcoming Catalysts (preview)

• Q4 2026Potential NDA approval for olverembatinib in CML in China70% success
• Q1 2027Phase 2 data readout for lisaftoclax in AML/MDS50% success
• Q2 2027Initiation of Phase 3 trial for lisaftoclax in CLL/SLL65% success